DuPont Decomposition

Why does VIVIMEDLAB earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

-18.6% = -28.6% × 0.19 × 3.48

Latest: FY2022

Profitability

Net Margin

-28.6%

-28.6% →-28.6%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.19x

0.19x →0.19x

Revenue per ₹ of assets

Leverage

Equity Multiplier

3.48x

3.48x →3.48x

Assets funded by equity vs debt

Historical Decomposition

Last 1 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr-0Cr-28.6%0.193.48-18.6%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for VIVIMEDLAB

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

VIVIMEDLAB DuPont Analysis — ROE -18.6% | YieldIQ